Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May 10;27(14):2339-55.
doi: 10.1200/JCO.2008.21.1953. Epub 2009 Apr 13.

Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings

Lisa Diller  1 , Eric J Chow, James G Gurney, Melissa M Hudson, Nina S Kadin-Lottick, Toana I Kawashima, Wendy M Leisenring, Lillian R Meacham, Ann C Mertens, Daniel A Mulrooney, Kevin C Oeffinger, Roger J Packer, Leslie L Robison, Charles A Sklar
Affiliations
Review

Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings

Lisa Diller et al. J Clin Oncol. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Clin Oncol. 2021 Nov 10;39(32):3650. doi: 10.1200/JCO.21.02324. J Clin Oncol. 2021. PMID: 34739771 No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Cumulative incidence of chronic health conditions (grade 1 to 5 and grade 3 to 5).
Fig 2.
Fig 2.
Cumulative incidence of chronic health conditions by exposure (grade 3 to 5 only). Survivors exposed to radiation in more than one anatomic site are included in each appropriate radiation curve in the right panel. RT, radiation therapy; CHEMO, chemotherapy; TBI, total body irradiation.
Fig 3.
Fig 3.
Probability of developing an underactive thyroid after diagnosis of Hodgkin's lymphoma. RT, radiation therapy.
Fig 4.
Fig 4.
Age- and sex-specific percentiles for height and body mass index (BMI) among brain cancer survivors by age at diagnosis (upper panel) and treatment types (lower panel).
Fig 5.
Fig 5.
Height standard deviation scores (SDS) across exposure groups by pubertal status at acute lymphoblastic leukemia diagnosis. Box height represents mean height SDS in the group. (*) P < .05; (**) P < .001 by t-test for differences. Sibs, siblings; Chemo, chemotherapy, CRT, cranial radiotherapy; CSRT, craniospinal radiotherapy.
Fig 6.
Fig 6.
Final height standard deviation score (SDS) according to original diagnosis and exposure to direct spinal radiation therapy (RT). (*) P < .05; (**) P < .0001.
Fig 7.
Fig 7.
Comparison of the number of second neoplasm (SN) estimated per 1,000 person-years for survivors who did and did not receive treatment with growth hormone, plotted against time since diagnosis (years). (gray line) 95% CI.
Fig 8.
Fig 8.
Percent of male and female survivors by primary diagnosis and body mass index category. ALL, acute lymphoblastic leukemia.
Fig 9.
Fig 9.
Scatterplot for unadjusted body mass index (BMI) by age at diagnosis of acute lymphoblastic leukemia for females treated with ≥ 20 Gy cranial radiotherapy.
Fig 10.
Fig 10.
The proportion of women who achieve menarche over time, adjusted for ethnicity, birth year, and abdominal radiotherapy. Compared with siblings, survivors treated with chemotherapy only (chemo) did not report menarche earlier (P = .76), in contrast to those treated with cranial radiotherapy (CRT; P < 0.01). Craniospinal radiotherapy (CSRT) was associated with delayed menarche compared with siblings (P < .01).
Fig 11.
Fig 11.
Cumulative incidents of osteonecrosis among survivors and a sibling comparison group starting 5 years after diagnosis.
Fig 12.
Fig 12.
Cumulative incidence of osteonecrosis among all survivors stratified by age at diagnosis.
Fig 13.
Fig 13.
Cumulative incidence of medical conditions reported ≥ 5 years after diagnosis. CRX only, chest radiation therapy only; PTC only, pulmonary toxic chemotherapy only; Both, CRX and PTC; Neither, neither CRX nor PTC.
Fig A1.
Fig A1.
Comparison of the number of second neoplasm (SN) estimated per 1,000 person-years for survivors who did and did not receive treatment with growth hormone, plotted against time since diagnosis (years). (gray line) 95% CI.
See this image and copyright information in PMC

References

    1. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA. 2003;290:1583–1592. - PubMed
    1. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:5277–5282. - PubMed
    1. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515–5523. - PMC - PubMed
    1. Mulrooney DA, Dover DC, Li S, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: A report from the Childhood Cancer Survivor Study. Cancer. 2008;112:2071–2079. - PubMed
    1. Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: A report from the childhood cancer survivor study. Pediatr Blood Cancer. 2005;44:643–653. - PubMed

Publication types

MeSH terms

Substances